Stryker Corporation (SYK) - Stock Analysis

Business Model

25%

3.7/5

3.66

Stryker's revenue base is procedure-driven medical devices, a mix of per-procedure implants, consumables, and capital equipment tied to Mako robotic placements. Demand is supported by demographic tailwinds in joint replacement, but 75% US concentration in FY2025 and exposure to deferrable elective procedures limit durability. Operating leverage is steady rather than software-like, with adjusted operating margin of 30.2% in Q4 2025.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.75

Forward visibility of revenue: backlog, contracts, retention

3.75

Summary

Revenue is driven by procedure volume across hip, knee, trauma, extremities, and neurosurgery, categories with demographic-driven demand. Stryker delivered 10.3% organic growth in FY2025 and guided to 8.0-9.5% organic growth for FY2026, with multi-year revenue continuity other than the FY2020 COVID shock.

3.75

Product Diversification10%

3.50

Diversification across product lines, segments, and customers

3.50

Summary

Two reportable segments in FY2025: MedSurg and Neurotechnology ($15.6B, 62% of sales) and Orthopaedics ($9.5B, 38%). Underneath sit trauma, extremities, knees, hips, instruments, endoscopy, medical, neurovascular, and neurocranial businesses. Segment-level concentration is offset by diverse underlying categories.

3.50

Geographic Diversification15%

2.50

Distribution across regions and home-market dependence

2.50

Summary

US revenue was roughly $16.94B (75%) of FY2025 sales, EMEA 12.8%, and Asia Pacific about 9%. International revenue is growing (EMEA +9.8% in FY2025), but the company remains heavily dependent on the US hospital market and its reimbursement environment.

2.50

Scalability20%

3.25

Ability to grow revenue without proportional cost increases

3.25

Summary

Capital-equipment manufacturing and implant production are asset-heavier than software but produce steady operating leverage. Adjusted operating margin reached 30.2% in Q4 2025, 100 basis points above Q4 2024. Mako razor-and-razorblade economics (capital placements plus disposables and implants) improve unit economics gradually rather than at a software pace.

3.25

Revenue Quality25%

3.75

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.75

Summary

Revenue is mission-critical for customer hospitals (no implant, no surgery) and largely repeat across aging-driven categories. It is transactional and capital-cycle rather than contractual subscription, placing quality above average without reaching the recurring-contract standard typical of software or MSO businesses.

3.75

Competitive Advantages

40%

The moat rests on surgeon preference, capital lock-in around Mako, and a broad innovation-driven product portfolio. Pricing power is constrained by hospital purchasing consortia and reimbursement pressure, and robotic leadership is being contested by Zimmer Biomet (ROSA) and J&J (Velys). Brand recognition is strong but does not translate into a quantified pricing premium over peers.

Pro dimensions

Competitive Advantages · Management · Risk Assessment